Long-term tolerability of fexofenadine in healthy volunteers

Clinical Drug Investigation

Volumn 18, Issue 4, 1999, Pages 317-328

  Nathan, Robert A ^a   Mason, Jolene ^b   Bernstein, David I ^c   Howland III, William C ^d   Kaiser, Harold B ^e   Meltzer, Eli O ^f   Segall, Nathan ^g  

^a Asthma & Allergy Associates PC and Research Center   (United States)

^b SANOFI   (France)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d HealthQuest Therapy/Res Inst Inc   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^g Family Allergy and Asthma Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; FEXOFENADINE;

ANEMIA; ARTICLE; BACKACHE; BILIARY TRACT DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAM; FATIGUE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERLIPIDEMIA; INSOMNIA; LEUKOPENIA; LONG TERM EXPOSURE; MULTICENTER STUDY; MYALGIA; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SINUSITIS; THORAX PAIN; VERTIGO; VIRUS INFECTION; VOLUNTEER;

EID: 0032752844     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199918040-00008     Document Type: Article

References (24)

1. Druce HM, Kaliner MA, Allergic rhinitis. JAMA 1988; 259 (2): 260-3
2. 1-receptor antagonist drugs. N Engl J Med 1994; 330 (231): 1663-70
3. Mathews KP. The urticarias. Current concepts in pathogenesis and treatment. Drugs 1985; 30: 552-60
4. 1-receptor antagonists. Comparative tolerability and safety. Drug Saf 1994; 10 (5): 350-80
5. 1-receptor antagonist. An EAACI position paper. Allergy 1996; 51: 666-75
6. Janssens MML, Howarth PH. The antihistamines of the nineties. Clin Rev Allergy 1993; 11: 111-53
7. Simons FER. The eternal triangle: Benefit, risk and cost of therapeutic agents. Ann Allergy Asthma Immunol 1996; 77: 337-40
8. Good AP, Rockwood R, Schad P. Loratadine and ventricular tachycardia. Am J Cardiol 1994; 74 (2): 207
9. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. J Am Med Assoc 1990; 264 (21): 2788-90
10. Woosley RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol 1996; 36: 233-52
11. Paul E, Berth-Jones J, Ortonne J-P, et al. Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: A placebo-controlled, parallel-group, dose-ranging study. J Derm Treat 1998; 9: 143-9
12. 1-blockade effect of fexotenadine. Ann Allergy Asthma Immumol 1997; 79: 530-2
13. 1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc 1998; 19: 135-41
14. Bernstein DI, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 443-8
15. Day JH, Briscoe MP, Welsh A, et al. Onset of action, efficacy and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997; 79: 533-40
16. Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther 1998; 64 (6): 612-21
17. Vermeeren A. O'Hanlon JF. Fexofenadine's effects, alone and with alcohol on actual driving and psychomotor performance. J Allergy Clin Immunol 1998; 101: 306-11
18. Pratt C, Mason J, Russell T, et al. Effect of fexofenadine HCl on corrected QT interval (QTc). Allergy 1997; 52 Suppl. 37: 67
19. Markham A, Wagstaff AJ. Fexofenadine. Drugs 1998; 55 (2): 269-76
20. Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532-6
21. Lippert C, Ling J, Brown P, et al. Mass balance and pharmacokinetics of fexofenadine HCl in healthy, male volunteers [abstract S390]. Pharm Res 1995; 12 Suppl. 9:
22. Robbins DK, Castles MA, Pack DJ, et al. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998; 19: 455-63
23. Data on file 0039; Hoechst Marion Roussel.
24. Finn AF, Kaplan A, Fretwell R, et al. Safety and efficacy of fexofenadine HCl in the treatment of chronic idiopathic urticaria (CIU). J Allergy Clin Immunol 1999: 103: S156